Document Detail


Hypofractionation for clinically localized prostate cancer.
MedLine Citation:
PMID:  23763885     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
This manuscript reviews the clinical evidence for hypofractionation in prostate cancer, focusing on data from prospective trials. For the purposes of this manuscript, we categorize hypofractionation as moderate (2.4-4 Gy per fraction) or extreme (6.5-10 Gy per fraction). Five randomized controlled trials have evaluated moderate hypofractionation in >1500 men, with most followed for >4-5 years. The results of these randomized trials are inconsistent. No randomized trials or other rigorous comparisons of extreme hypofractionation with conventional fractionation have been reported. Prospective single-arm studies of extreme hypofractionation appear favorable, but small sample sizes preclude precise estimates of efficacy and short follow-up prevents complication estimates beyond 3-5 years. Over the next several years, the results of 3 large noninferiority trials of moderate hypofractionation and 2 randomized trials of extreme hypofractionation should help clarify the role of hypofractionation in prostate cancer therapy.
Authors:
Alvin R Cabrera; W Robert Lee
Related Documents :
23324165 - Early results of prostate cancer radiation therapy: an analysis with emphasis on resear...
24023525 - Non-steroidal anti-inflammatory drugs, variation in inflammatory genes, and aggressive ...
9636835 - A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to ...
23510155 - Early versus deferred androgen suppression therapy for patients with lymph node-positiv...
24305765 - Psychosocial impact of cancer.
24219455 - Kidney cancer.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Seminars in radiation oncology     Volume:  23     ISSN:  1532-9461     ISO Abbreviation:  Semin Radiat Oncol     Publication Date:  2013 Jul 
Date Detail:
Created Date:  2013-06-14     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9202882     Medline TA:  Semin Radiat Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  191-7     Citation Subset:  IM    
Copyright Information:
Copyright © 2013 Elsevier Inc. All rights reserved.
Affiliation:
Department of Radiation Oncology, Duke Cancer Institute, Durham, NC. Electronic address: alvin.cabrera@duke.edu.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Comparing Dosimetric, Morbidity, Quality of Life, and Cancer Control Outcomes After 3D Conformal, In...
Next Document:  Management of prostate cancer in elderly men.